collection of stools

PreclinicalBiologic

UUniversity Hospital, Toulouse

collection of stools is one of 60 biologic programs targeting Urothelial Carcinoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Urothelial CarcinomaActive, not recruiting

Progressive Multifocal LeukoencephalopathyActive, not recruiting

Urothelial CarcinomaPreclinical

Active, not recruiting

Progressive Multifocal LeukoencephalopathyPreclinical

Active, not recruiting

Competition

Competitive Landscape

200 competitors in Urothelial Carcinoma

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

26 2

Gemzar

Johnson & Johnson

Phase 3

24 3

Tecentriq

Roche

Phase 3

18 4

Opdivo

Bristol-Myers Squibb

Phase 3

12 5

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

18 6

Taxol

Teva

Phase 3

4 7

Beyfortus

BeiGene

Phase 3

3 8

Paraplatin

AAvyxa

Phase 3

10 9

Folvite

Eli Lilly

Phase 3

1 10

Vectibix

Amgen

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2031

Recruiting

Urothelial Carcinoma

NCT04970472

Recruiting

TED

NCT04970459

Clinical

Trials by Indication[1]

Urothelial Carcinoma1 trial

Bio Clinical Collection of Urothelial Carcinoma

Recruiting·UUniversity Hospital, Toulouse··NCT04970472·1,000 enrolled

TED1 trial

Biological Collection for Marfan and Related Syndromes

Recruiting·UUniversity Hospital, Toulouse··NCT04970459·300 enrolled

Progressive Multifocal Leukoencephalopathy1 trial

Dynamics of T Cell Expression of Immune Checkpoint Molecules in Progressive Multifocal Leukoencephalopathy

Completed·UUniversity Hospital, Toulouse·N/A·NCT04453917·22 enrolled

Prospective1 trial

Prospective Cohort Assessing the Role of the Genotoxin Colibactin From Escherichia Coli B2 in the Genesis of NASH

Completed·UUniversity Hospital, Toulouse··NCT02390232·176 enrolled

Unspecified1 trial

Feasibility Study of a New Immunoglobulin E (IgE) Assay Method

Recruiting·UUniversity Hospital, Toulouse··NCT04751760·1,376 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for collection of stools. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — collection of stools compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for collection of stools. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Toulouse company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: UUniversity Hospital, Toulouse

collection of stools

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2031

Trials by Indication[1]

Urothelial Carcinoma1 trial

TED1 trial

Progressive Multifocal Leukoencephalopathy1 trial

Prospective1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News